Trial | NCT00543426  Report issue

Official Title

Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    fuzhenghuayu ...

  • Study Participants

    200
The primary purpose of the trial is adopted Fuzheng Huayu tablets against posthepatitic cirrhosis, and to build a standard evaluation system for efficacy of traditional Chinese medicine (TCM).

The second purpose is according to the international clinical guideline and the specialty of TCM to build a standard clinical trial regulation for traditional Chinese medicine.
Study Started
Sep 30
2007
Primary Completion
May 31
2009
Study Completion
Jun 30
2009
Last Update
Mar 07
2013
Estimate

Drug Fuzheng Huayu Tablets

Tablet,three times a day,four tablets one time

Drug sham Fuzheng Huayu Tablets (placebo)

Tablet, three times a day, four tablets one time

1 Experimental

Fuzheng Huayu Tablets

2 Sham Comparator

sham Fuzheng Huayu Tablets

Criteria 

Inclusion Criteria:

Clinical diagnosis of B Post hepatitic cirrhosis.
Male or female patients between 18~65 years old.
Written informed consent.

Exclusion Criteria:

Child-Pugh C above 12, or ALT > 2×ULN, TBiL > 2×ULN, or combined with hepatic encephacopathy, Obstinate ascites, bleeding tendency, hepato-renal syndrome, or primary liver cancer.
Combined with severe heart, gallbladder, kidney, endocrine system, hemopoietic system or nervous system disease.
Deformed man by the law.
Pregnancy or breast feeding women, or unwilling to have contraception.
Irritability body constitution, or irritability of the Fuzheng Huayu Capsules.
Enter other trials lately one month.
Other cause of cirrhosis.
No Results Posted